Renhe Pharmacy Co.,Ltd Income Statement

Financials in millions CNY. Fiscal year is January - December.

Millions CNY. Fiscal year is Jan - Dec.

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Mar '26 Mar 31, 2026	Dec '25 Dec 31, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Jan '23 Jan 1, 2023	Jan '22 Jan 1, 2022
Operating Revenue	3,680	3,536	3,995	4,927	5,075	4,841
Other Revenue	-	-	79.63	105.17	78.56	94.45
Revenue	3,680	3,536	4,075	5,032	5,153	4,936
Revenue Growth (YoY)	-3.74%	-13.21%	-19.02%	-2.35%	4.41%	15.38%
Cost of Revenue	2,322	2,229	2,542	3,187	3,308	3,071
Gross Profit	1,358	1,307	1,533	1,845	1,845	1,865
Selling, General & Admin	583.07	601.25	748.38	804.72	864.65	850.05
Research & Development	44.39	45.07	43.85	46.36	50.54	52.14
Other Operating Expenses	7.91	-55.85	40.84	46	44.46	37.76
Operating Expenses	635.38	590.46	861.67	901	966.32	942.38
Operating Income	723.08	716.72	671.27	943.83	878.95	922.49
Interest Expense	-	-	-0.17	-0.35	-0.43	-0.98
Interest & Investment Income	74.18	83.43	86.33	87.92	70.49	88.18
Currency Exchange Gain (Loss)	-	-	-	-	-0	-0
Other Non Operating Income (Expenses)	-33.37	-33.25	-3.15	-3.39	-0.69	-2.01
EBT Excluding Unusual Items	763.9	766.91	754.29	1,028	948.33	1,008
Impairment of Goodwill	-	-	-45	-31.33	-27.89	-
Gain (Loss) on Sale of Investments	22.71	25.12	16.03	16.83	22.11	-0.03
Gain (Loss) on Sale of Assets	2.05	2.05	1.37	-0.27	0.34	16.84
Asset Writedown	-129.23	-129.18	-60.01	-176.3	-4.53	-1.44
Legal Settlements	-	-	-2.3	-	-	-
Other Unusual Items	-	-	110.24	61.91	15.18	11.37
Pretax Income	659.43	664.9	774.62	898.86	953.54	1,034
Income Tax Expense	190.28	177.24	208.03	269.45	242	234.54
Earnings From Continuing Operations	469.15	487.66	566.59	629.41	711.54	799.87
Minority Interest in Earnings	-99.88	-94.45	-84.67	-62.15	-137.11	-134.85
Net Income	369.28	393.21	481.91	567.26	574.43	665.02
Net Income to Common	369.28	393.21	481.91	567.26	574.43	665.02
Net Income Growth	-21.25%	-18.41%	-15.04%	-1.25%	-13.62%	14.62%
Shares Outstanding (Basic)	1,404	1,404	1,377	1,384	1,401	1,385
Shares Outstanding (Diluted)	1,404	1,404	1,395	1,400	1,401	1,385
Shares Change (YoY)	0.67%	0.65%	-0.34%	-0.08%	1.13%	9.85%
EPS (Basic)	0.26	0.28	0.35	0.41	0.41	0.48
EPS (Diluted)	0.26	0.28	0.35	0.41	0.41	0.48
EPS Growth	-21.77%	-18.93%	-14.76%	-1.17%	-14.58%	4.35%
Free Cash Flow	796.56	776.72	271.54	312.92	1,049	277.93
Free Cash Flow Per Share	0.57	0.55	0.20	0.22	0.75	0.20
Dividend Per Share	-	-	0.150	0.200	0.200	0.100
Dividend Growth	-	-	-25.00%	-	100.00%	-50.00%
Gross Margin	36.91%	36.96%	37.62%	36.66%	35.81%	37.78%
Operating Margin	19.65%	20.27%	16.47%	18.76%	17.06%	18.69%
Profit Margin	10.04%	11.12%	11.83%	11.27%	11.15%	13.47%
Free Cash Flow Margin	21.65%	21.96%	6.66%	6.22%	20.35%	5.63%
EBITDA	838.16	831.94	787.04	1,079	990.73	1,006
EBITDA Margin	22.78%	23.52%	19.31%	21.44%	19.23%	20.37%
D&A For EBITDA	115.08	115.22	115.77	134.89	111.78	83.15
EBIT	723.08	716.72	671.27	943.83	878.95	922.49
EBIT Margin	19.65%	20.27%	16.47%	18.76%	17.06%	18.69%
Effective Tax Rate	28.85%	26.66%	26.86%	29.98%	25.38%	22.67%
Revenue as Reported	-	-	4,075	5,032	5,153	4,936
Advertising Expenses	-	-	161.72	202.54	217.09	215

Updated Mar 31, 2026. Source: S&P Global Market Intelligence. Standard template. Financial Sources.